<DOC>
	<DOCNO>NCT01860417</DOCNO>
	<brief_summary>In study want evaluate clinical use allogenic mesenchymal stem cell ( MSC ) , obtain bone marrow healthy donor , treatment Degenerative Disc Disease ( DDD ) . The trial base previous result autologous MSC ( Orozco et al. , Transplantation 92 : 822-828 ; 2011 ) . Here propose phase I-II trial , prospective , randomize , blind , control treatment DDD use MSV , Good Manufacturing Practice ( GMP ) -compliant expand bone marrow MSC ( MSV , PEI Num . 10-134 ) . The assay consist two arm 12 patient one . Patients experimental arm give single intra-discal transplantation MSV ( 25 million 2 ml ) . Control patient infiltrated paravertebral muscle close lesion 2 ml 1 % mepivacain . We shall follow evolution pain , disability quality life well disc fluid content Magnetic Resonance Imaging ( T2-calibrated ) .</brief_summary>
	<brief_title>Treatment Degenerative Disc Disease With Allogenic Mesenchymal Stem Cells ( MSV )</brief_title>
	<detailed_description />
	<mesh_term>Back Pain</mesh_term>
	<mesh_term>Low Back Pain</mesh_term>
	<mesh_term>Spinal Diseases</mesh_term>
	<mesh_term>Intervertebral Disc Degeneration</mesh_term>
	<mesh_term>Intervertebral Disc Displacement</mesh_term>
	<mesh_term>Mepivacaine</mesh_term>
	<criteria>Degenerative disease one two lumbar disc predominant back pain conservative treatment ( physical medical ) 6 month . Fibrous ring capable hold cell implantation , demonstrate RMI image ( stag 2 , 3 4 Adams ) . Decrease disc height 20 % ( radiographic measurement side image ) . Absence spinal infection . Haematological biochemical analysis wit significant alteration contraindicate intervention . The patient able understand nature study . Informed write consent patient . Age 75 18 legally dependent Allergy gentamicin , bovine , cattle horse serum . Congenital acquire disease lead spine deformation may upset cell application . Spinal segmental instability , spinal canal stenosis , isthmus pathology condition may compromise study Modic III change MRI image ( 31 ) . Overweight body mass index ( mass Kg/size m2 ) great 35 ( obesity grade II ) . Pregnancy breastfeed Neoplasia Immunosuppression Participation another clinical trial treatment another investigational product within 30 day prior inclusion study . Other condition may , accord medical criterion , discourage participation study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Degenerative Disc Disease ,</keyword>
	<keyword>Intervertebral Disc Disease</keyword>
	<keyword>Low Back Pain</keyword>
	<keyword>Nucleus pulposus</keyword>
	<keyword>Stem cell</keyword>
	<keyword>Cellular therapy</keyword>
	<keyword>Regenerative therapy</keyword>
	<keyword>Mesenchymal stem cell</keyword>
	<keyword>Bone marrow</keyword>
	<keyword>Musculoskeletal Diseases</keyword>
	<keyword>Mesenchymal Stromal Cells ( allogenic )</keyword>
</DOC>